Marrone Bio Innovations’ BioUnite&#x2122 plan gives new options to California growers


BioUnite plan enables California grape and almond growers to address mid-season pest management requirements

DAVIS, Calif., July 9, 2019 – Marrone Bio Innovations Inc. (the “Company” or “MBI”) (NASDAQ: MBII), a major developer of bio-primarily based items for pest management and plant well being, now announced that California almond and grape growers are gaining an edge as they address mid-season pest manage difficulties by means of the implementation of the company’s novel BioUnite plan.

Marrone Bio launched BioUnite to present growers with integrated pest management applications that harness the energy of biology with the overall performance of chemistry resulting in a extra effective meals production technique that is very affordable, sustainable, protected, and straightforward to use. BioUnite offers distinct biological prescriptions that growers integrate into their operations, taking the guesswork out of working with biologically derived supplies with their common crop protection plan.

Marrone Bio supports the BioUnite plan with study that spans from initial discoveries by means of hands-on field trials. Almond growers are at present treating for navel orangeworm larvae, which bore into and consume the nut fruit, damaging good quality, and yield, and decreasing the worth farmers get for their crop. In substantial 2018 field trials, Marrone Bio Innovations’ Venerate® biological insecticide, when tank mixed with a common insecticide, lowered nut harm by an added two% as compared with the common insecticide plan. This Venerate BioUnite plan benefits in a six-to-1 return on investment to the grower. In grapes, the BioUnite idea integrates Haven® plant anxiety manager into the grower vine management plan. Field trials demonstrated Haven resulted in an 18% yield enhance, delivering a six-to-1 return on investment. Also in grapes, when Regalia® biofungicide was added to the  growers’ illness management plan, Regalia offered a 57% improvement in illness manage as compared to the common remedy.

“Growers about the globe are faced with the challenge to meet diverse customer demands for higher option, affordability, and availability,” mentioned Kevin Hammill, Chief Industrial Officer for Marrone Bio Innovations. “Growers have to have revolutionary, expense-powerful tools to operate in a dynamic, altering marketplace. We think that BioUnite gives growers an thrilling new resource to meet customer demands,” concluded Hammill.

About Marrone Bio Innovations

Marrone Bio Innovations Inc. (NASDAQ: MBII) is a development-oriented firm major the movement to extra a sustainable globe by means of the discovery, improvement and sale of revolutionary biological items for crop protection, plant well being and waterway systems remedy that aid prospects operate extra sustainably even though escalating their return on investment. MBI has screened more than 18,000 microorganisms and 350 plant extracts, leveraging its in-depth know-how of plant and soil microbiomes enhanced by sophisticated molecular technologies and all-natural solution chemistry to quickly create seven solution lines. Supported by a robust portfolio of more than 400 issued and pending patents, MBI’s at present out there industrial items are Regalia®, Stargus®, Grandevo®, Venerate®, Majestene®, Haven® and Amplitude®, Zelto® and Zequanox®, with a breakthrough bioherbicide and biofumigant in the company’s solution pipeline.

Find out extra about Marrone Bio Innovations at Comply with us on social media: Twitter, LinkedIn and Instagram.

Marrone Bio Innovations Forward-Seeking Statements

This press release includes forward-hunting statements that involve substantial dangers and uncertainties. All statements, other than statements of historical information, incorporated in this press release concerning method, future operations and plans, which includes assumptions underlying such statements, are forward-hunting statements, and ought to not be relied upon as representing MBI’s views as of any subsequent date. Examples of such statements include things like the prospective of MBI’s items which includes Venerate, Haven and Regalia in BioUnite applications and industry projections. Such forward-hunting statements are primarily based on info out there to the Organization as of the date of this release and involve a quantity of dangers and uncertainties, some beyond the Company’s manage, that could result in actual benefits to differ materially from these anticipated by these forward-hunting statements, which includes climate, regulatory and other aspects affecting demand for the MBI’s items, any difficulty in advertising MBI’s items in its target markets, competitors in the industry for pest management items, lack of understanding of bio-primarily based pest management items by prospects and growers. Further info that could lead to material adjustments in MBI’s overall performance is contained in its filings with the SEC. MBI is beneath no obligation to, and expressly disclaims any duty to, update or alter forward-hunting statements contained in this release, no matter if as a outcome of present info, future events or otherwise.

Marrone Bio Innovations Speak to:
Kevin Hammill, Chief Industrial Officer
Phone: +1 (530) 750-2800
E-mail: [email protected]

Investor Relations:
Greg Falesnik
Managing Director
MZ Group – MZ North America
Principal: 949-385-6449
[email protected]


Latest posts